Literature DB >> 9845322

The mode of action of Y13-259 scFv fragment intracellularly expressed in mammalian cells.

A Cardinale1, M Lener, S Messina, A Cattaneo, S Biocca.   

Abstract

The anti-p21ras Y13-259 single-chain Fv fragment (scFv) neutralizes the activity of p21-ras when intracellularly expressed in different systems. We have studied the mode of action of this inhibition in 3T3 K-ras fibroblasts and demonstrated that (i) this antibody fragment is highly aggregating when cytoplasmically expressed and (ii) the p21-ras antigen is sequestered in these aggregates in an antibody-dependent manner. This co-segregation leads to an efficient inhibition of DNA synthesis. These results suggest that an antigen can be diverted from its normal location inside the cells in an antibody mediated way, prospecting a new mode of action for intracellular antibodies in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9845322     DOI: 10.1016/s0014-5793(98)01369-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  Selection of antibodies for intracellular function using a two-hybrid in vivo system.

Authors:  M Visintin; E Tse; H Axelson; T H Rabbitts; A Cattaneo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Role of native-state topology in the stabilization of intracellular antibodies.

Authors:  G Settanni; A Cattaneo; A Maritan
Journal:  Biophys J       Date:  2001-11       Impact factor: 4.033

3.  Intrabody expression in eukaryotic cells.

Authors:  Laurence Guglielmi; Pierre Martineau
Journal:  Methods Mol Biol       Date:  2009

Review 4.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

5.  Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.

Authors:  Erik Kvam; Michael R Sierks; Charles B Shoemaker; Anne Messer
Journal:  Protein Eng Des Sel       Date:  2010-04-08       Impact factor: 1.650

Review 6.  Direct inhibition of RAS: Quest for the Holy Grail?

Authors:  Russell Spencer-Smith; John P O'Bryan
Journal:  Semin Cancer Biol       Date:  2017-12-14       Impact factor: 15.707

Review 7.  Therapeutic targeting of RAS: New hope for drugging the "undruggable".

Authors:  Imran Khan; J Matthew Rhett; John P O'Bryan
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2019-10-31       Impact factor: 4.739

8.  Novel antibody derivatives for proteome and high-content analysis.

Authors:  Katrin Schmidthals; Jonas Helma; Kourosh Zolghadr; Ulrich Rothbauer; Heinrich Leonhardt
Journal:  Anal Bioanal Chem       Date:  2010-04-07       Impact factor: 4.142

9.  Characterization of antibodies in single-chain format against the E7 oncoprotein of the human papillomavirus type 16 and their improvement by mutagenesis.

Authors:  Maria Gabriella Donà; Colomba Giorgi; Luisa Accardi
Journal:  BMC Cancer       Date:  2007-01-31       Impact factor: 4.430

10.  Synaptic plasticity through activation of GluA3-containing AMPA-receptors.

Authors:  Maria C Renner; Eva Hh Albers; Nicolas Gutierrez-Castellanos; Niels R Reinders; Aile N van Huijstee; Hui Xiong; Tessa R Lodder; Helmut W Kessels
Journal:  Elife       Date:  2017-08-01       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.